CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
APAC
CANADA

About Us

Conference

Partner With Us

  • Europe
    • US
    • APAC
    • CANADA
    • LATAM
  • Drug Discovery
    Biotech
    Cancer Immunotherapy
    Cell and Gene Therapy Companies
    Clinical Trial Management
    Drug Discovery and Development
    Genomics
    Therapeutics
    Women's Health
  • Biomanufacturing
    Biomanufacturing
    Bioprocessing
    CDMO
    Clinical Laboratory Services
    CRO
    Microgravity R&D
    Supplements
  • Business Services
    Clinical Research Training
    Life Science Consulting
    Life Science Logistics
    Life Science Marketing
  • Leadership Perspectives
  • Innovation Insights
  • News
  • Magazines
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

The Impact of Advanced Delivery Systems on the European Nutraceutical Market

Europe’s nutraceutical market is shifting toward advanced liquid formulations using nanotechnology and precision delivery systems to improve absorption, convenience, and personalised nutrition, replacing traditional pills. 

By

Life Sciences Review | Thursday, October 22, 2026

The European nutraceutical market is shifting from traditional solid dosage forms to advanced liquid formulations. This change is driven by consumer demand for convenient, pill-free options and the need for greater efficacy, leading to significant innovation in fluid delivery systems.


The market now focuses not only on ingredients but also on how effectively they are delivered. "Pill fatigue," or consumer reluctance to take multiple tablets daily, has driven growth in functional beverages, shots, drops, and sprays. The most significant advances involve nanotechnology, improved bioavailability, and precision delivery systems, which are transforming nutritional absorption.

Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.


Redefining Potency at the Molecular Level


Nanotechnology is increasingly being integrated into food and nutrition science. European formulators are shifting from macro-emulsions and suspensions, which often experience phase separation and poor homogeneity, to thermodynamically stable nanostructured systems. This shift aims to address the low water solubility of many high-value bioactive compounds, including curcumin, CoQ10, fat-soluble vitamins (A, D, E, K), and omega-3 fatty acids.


Nanoemulsions have become a leading technology in this field. By reducing droplet sizes to 20 to 200 nanometers, they significantly increase surface area for absorption. Unlike traditional emulsions, nanoemulsions are often transparent or translucent, making them suitable for clear functional waters and beverages without affecting visual appeal. Their structure prevents gravitational separation, such as creaming or sedimentation, resulting in excellent shelf-life stability. In the European market, where clean-label standards are essential, there is a clear trend toward using natural emulsifiers such as quillaja saponins, sunflower lecithin, or pea protein instead of synthetic surfactants.


Liposomal encapsulation is a key component of this technological shift. Liposomes are spherical vesicles made of one or more phospholipid bilayers, closely resembling human cell membranes. This biomimetic property enables liposomes to fuse with cellular membranes in the gastrointestinal tract, allowing direct intracellular delivery of their contents. Recent European advancements have led to "stealth" liposomes, which are surface-modified to resist degradation by gastric acids and enzymes, ensuring that the active payload reaches the small intestine intact.


Solid lipid nanoparticles (SLNs) are also emerging as a strong alternative. They consist of a solid lipid core matrix that can solubilise lipophilic molecules. SLNs provide both physical stability and controlled release, gradually delivering nutrients into the bloodstream to maintain therapeutic levels, which is essential for nutrients that require sustained presence in the body.


Mastering Bioavailability: The Science of Absorption


In the context of liquid nutraceuticals, bioavailability enhancement has moved beyond simple solubility to encompass the active modulation of physiological uptake mechanisms. The industry is increasingly relying on lymphatic transport as the primary absorption route. In traditional digestion, nutrients travel through the portal vein to the liver, where first-pass metabolism can degrade active compounds before they reach systemic circulation. By incorporating lipophilic actives into lipid-based nanocarriers such as long-chain triglyceride nanoemulsions, formulators enable these nutrients to be packaged into chylomicrons. Chylomicrons enter the lymphatic system directly, bypassing the liver and delivering active ingredients into the bloodstream. This strategy has significantly improved the systemic availability of challenging molecules such as resveratrol and cannabinoids.


A significant advancement is the use of bio-enhancers, which naturally inhibit metabolic enzymes and efflux pumps that remove nutrients. In Europe, advanced liquid formulations now combine primary nutrients with synergistic botanical extracts. For example, piperine from black pepper and gingerols are co-formulated to inhibit P-glycoprotein, a transporter that expels foreign substances from cells. Temporarily reducing this defence increases absorption of the primary nutrient.


Self-Nanoemulsifying Drug Delivery Systems (SNEDDS) are expanding from pharmaceutical to nutraceutical applications. These anhydrous liquid pre-concentrates form a fine oil-in-water nanoemulsion when exposed to the gut's aqueous environment. This process delivers nutrients to the intestinal lining in an optimal, absorbable form, regardless of whether the consumer is fasted or fed. As a result, this technology provides consistent efficacy across individuals with different digestive capabilities.


Next-Generation Delivery Systems: Precision and Convenience


Functional beverages and waters are evolving beyond basic fortification. The industry is moving toward matrix-optimised products, where the liquid base enhances ingredient delivery. Examples include structured waters and hydrogels that protect ingredients from oxidation. Advances in technology now allow for the suspension of incompatible ingredients, such as oil-soluble vitamins and water-soluble minerals, in a single clear liquid. This is often achieved using micelles, which isolate reactive components and prevent degradation.


Liquid Shots and Drops offer highly concentrated delivery in a compact format, making them ideal for on-the-go European consumers. These products use high-viscosity, shear-thinning fluids that stay stable in the bottle and flow easily when dispensed. Precision droppers and airless pump systems are now standard, enabling users to adjust their dose accurately, which supports the trend toward personalised nutrition. Users can take 1ml or 1.5ml based on their daily needs, a flexibility not possible with fixed-dose capsules.


Sublingual and buccal sprays are gaining prominence by delivering nutrients through the highly vascularized oral mucosa, bypassing the digestive system. For nutrients such as Vitamin B12 or melatonin, where rapid onset is essential, nano-sized mists enable near-instant absorption into the bloodstream. Improved nozzle technology ensures consistent particle size and precise, reproducible dosing with each spray.


Bitterness-masking technologies have transformed the sensory experience of liquid supplements. Since liquids expose taste buds to active ingredients, flavour is essential. Molecular encapsulation serves as a taste barrier by trapping bitter molecules in a neutral shell that dissolves in the stomach. This enables the creation of palatable liquids with herbs such as ashwagandha or valerian root, which are typically harsh-tasting.


The European liquid nutraceutical industry is shifting from a "more is better" mindset to a "smarter is better" approach. By applying nanotechnology, optimising absorption pathways, and developing user-focused delivery systems, the industry is redefining standards for supplements. These liquid formulations represent the future of preventative health: potent, precise, and easily integrated into daily routines. As these technologies advance, the gap between pharmaceutical efficacy and nutraceutical safety is narrowing, offering a new era of high-performance health optimisation for European consumers.


More in News

Therapeutics Advance through Precision Medicine and Biopharmaceutical Innovation

The practice of therapeutics has grown to be a central issue in modern medicine, as far as the pharmaceutical, biotechnological and health care providers' continued interest in precision medicine, biologics innovation and targeted therapy development is concerned. As this field continues to revolutionize health care services to be involved in diagnosis, treatment and managing chronic disease, cancer, rare disease, etc., the market involves biologic therapeutics, small-molecule drugs, cell/gene therapies, immunotherapy, antibody-based treatment and precision medicine platforms designed to ameliorate clinical outcomes and improve longterm management of disease. The global therapeutics market continues to grow steadily as chronic disease rates rise, populations age and healthcare investment increases worldwide. Industry estimates now place global pharmaceutical spending above USD 1.5 trillion annually, supported by continued growth in oncology research, biologic development and personalized healthcare. Healthcare organizations and pharmaceutical developers are also becoming more selective in how they evaluate therapeutic capabilities. Clinical effectiveness remains critical, but companies are also looking closely at treatment durability, manufacturing scalability, regulatory readiness and long-term patient outcomes alongside reimbursement strategy. Precision medicine continues to drive and revolutionize the therapeutics market. Hospitals and doctors depend on genomic sequencing and biomarker-driven therapeutic approaches in order to target treatments and avoid non-essential ones. That change leads to higher demand for therapeutics that can target specific pathways better than typical pharmaceuticals. Oncology is one of the most significant therapeutic segments. Pharmaceutical companies continue to develop antibody-drug conjugates, immunotherapy, and targeted biologics programs aiming for higher survival rates and fewer side effects. Rare disease treatment has also received growing investment attention in recent years. Biotechnology organizations increasingly focus on therapies designed for inherited conditions and patient populations that historically have had limited treatment options. Biologics and Precision Therapies Drive Investment Biologics remain one of the fastest-growing areas within the therapeutics market. Monoclonal antibodies, recombinant proteins and cell-based therapies continue expanding across oncology, autoimmune disease and neurological care. Facility infrastructure for biopharmaceuticals has gained increasing focus as a key investment area, as new biologics often need unique production equipment and controlled laboratory conditions. Cell and gene therapies are also being targeted by increasing levels of investment, and researchers continue to probe therapies to control cellular function and individualize responses targeting specific disease-causing genes. Precision therapies are also driving changes in pharmaceutical strategy. Targeted drug discovery now is emphasizing therapies driven by analysis of biomarkers, gene expression profiles and individual response characteristics. Molecular diagnostics continue to strengthen therapeutic development because healthcare providers increasingly prioritize earlier disease detection and personalized treatment planning. “The therapeutics market is moving toward a future shaped by precision medicine, advanced biologics and more personalized healthcare systems.” In therapeutic research environments too, sophisticated data analysis systems are gaining greater importance. Organizations in the pharmaceutical sector are now dependent on tools that enable molecular analysis, modeling and clinical trial planning to be done faster. The interoperable research infrastructure and digital laboratory systems are also enhancing collaboration between healthcare institutions, biotech organizations and academic bodies. Clinical Research and Regulation Continue to Evolve Clinical research has increased in complexity as novel therapies become prevalent in all healthcare markets. Drug developers are now dependent on the decentralized model for clinical trials as well as on the use of digital monitoring and predictive models. Oncology and precision medicine studies are increasingly adopting a biomarker-driven approach due to the requirement for stringent patient selection criteria for target therapy administration. Regulatory agencies are also adopting new models for approvals to meet innovation demands with novel biologics and advanced therapies. Expedited pathways and special programs for review are being applied across more of the health sectors. Although the market is growing significantly, therapeutic developers continue to be under significant regulatory and financial pressure. While lengthy regulatory pathways are inevitable given that advanced therapies impact long-term safety and treatment efficacy, manufacturing scale-up remains another significant industry-wide hurdle. Personalized therapies and biologics require unique production processes, which can complicate development and raise costs of commercialization. Healthcare providers and payers also continue evaluating reimbursement models surrounding advanced therapeutics. Long-term clinical value, treatment durability and healthcare cost reduction increasingly influence decisions surrounding biologic and gene-based therapies. Another significant challenge to therapeutic manufacturing and distribution is supply-chain reliability. Availability, transport and the time-sensitive nature of biological therapies remain dominant issues. Data and Digital Technologies Reshape Development Analytics based on data still change the paradigm of therapeutics R&D. High-powered computer programs now aid drug discovery scientists in locating therapeutics, assessing molecule interactions and refining the toxicity evaluation. The use of data integration is becoming a key competitive advantage throughout the development of therapeutics. Businesses are now leveraging the power of interconnected systems that allow the compilation of genomic information, laboratory analytics and clinical trial information within research platforms. Therapeutic research is also benefiting from digital health technology and remote patient monitoring systems. With ongoing improvements and broader usage of wearables and connected healthcare systems, we will see ever more real-time patient data collection that will provide value for assessing long-term therapeutic response. Another trend shaping the therapeutic area is research collaboration, where the healthcare systems, biotechnology companies and pharmaceutical organizations are partnering to bring therapeutic development and commercialization processes forward. Another trend that still remains in the industry is the lack of a highly skilled workforce, which affects Biotechnology, Biologics Manufacturing and Pharmaceutical Analytics. A demand exists for more highly trained scientific professionals to support the development of novel therapies. The Future of Therapeutics The therapeutics market is moving toward a future shaped by precision medicine, advanced biologics and more personalized healthcare systems. Immunotherapies, genebased treatments and targeted biologics are expected to continue expanding across healthcare systems during the next decade. Advanced data analysis technologies may also play a larger role in molecular modeling, predictive drug development and clinical trial optimization as pharmaceutical organizations work to improve research efficiency and shorten development timelines. Personalized medicine strategies are expected to become even more advanced as healthcare providers increasingly rely on genomic analysis and biomarker-driven therapeutic planning. Healthcare organizations and pharmaceutical developers are also becoming more selective about longterm partnerships. Companies increasingly prefer partners capable of supporting scalable manufacturing, regulatory readiness and continuous scientific advancement. Therapeutics now plays a far more strategic role across healthcare innovation, biotechnology research and long-term disease management. Organizations that understand the scientific, regulatory and manufacturing changes shaping the sector will be better positioned to improve patient outcomes, strengthen research capabilities and support the future of precision healthcare. ...Read more

Selecting Psychological and Dependency Treatment Providers for Confidential Care

Mental health and addiction treatment often involves psychiatric care and physical health needs at the same time, so it's hard to tell what a provider is actually responsible for just by reading their list of services. When an organization arranges treatment for someone, it must consider whether the program is clinically appropriate, how well it protects the person's privacy, and what a residential stay will realistically require of them. A quiet, private setting can help people engage with their recovery, but being tucked away doesn't make up for proper medical care. A proper clinical assessment helps identify an individual's immediate needs and ensures they receive care from the right professionals. Mental health concerns, dependency issues and physical conditions can influence one another and shape the treatment process. Before choosing a provider, organizations should understand who carries out the initial assessment, how specialists are involved in treatment decisions and what happens when a patient needs care beyond the provider's expertise. Offering multiple services is not enough; clear clinical responsibility is essential to ensuring appropriate care. Keeping treatment private takes more than a simple assurance of confidentiality. Shared accommodation, waiting rooms and travel arrangements can make it difficult for patients to avoid unwanted attention. Providers should consider these factors when planning stays and appointments while making sure medical care remains accessible. They must also be clear about what information can be shared. Organizations paying for treatment may need updates on practical arrangements, but medical information should remain private unless the patient agrees to share it. These details should be settled before treatment starts. Coordinating different medical services is equally important. Psychiatry may lead the treatment process, while other specialists, such as physicians and nutritionists, address additional health needs. However, having several specialists does not guarantee that they work together effectively. Providers must ensure that clinicians communicate, treatment decisions remain consistent and someone takes responsibility when care plans need to change. Additional therapies and wellness equipment should also serve a clear purpose. The availability of these facilities does not necessarily make them suitable for every patient's needs. “Kusnacht Practice schedules its doctors to visit residents for therapies, while its small clinic provides access to services including blood draws.” Continuity of care should be planned before a patient enters residential treatment. Organizations need to understand how the treatment team monitors progress, who can make changes to care and what support is available after discharge. These details should be confirmed rather than assumed from the provider's list of services. Responsibilities for outside services must also be clearly defined, particularly when medical treatment and residential accommodation are combined. Without proper coordination, patients may be left unsure of where to turn once intensive treatment ends. Individual villas near Lake Zurich provide the residential setting for Kusnacht Practice’s psychological and dependency treatment. Kusnacht Practice schedules its doctors to visit residents for therapies, while its small clinic provides access to services including blood draws. Its treatment structure encompasses mental health care, internal medicine, biomolecular restoration and hospitality. The biomolecular work includes checking for nutrient deficiencies and supporting changes in nutrition and exercise habits, including supplementation. It also describes body and brain scans alongside cognitive performance services, although their application to specific diagnoses was not established in the interview. Individual accommodation and visiting doctors allow consultations without routine contact between residents, addressing a significant confidentiality requirement in sensitive residential treatment. ...Read more

Advanced Chromatography at the Intersection of Nutraceuticals and Gene Therapies in Europe

Europe’s health innovation sector is rapidly evolving, narrowing the gap between daily wellness and advanced medicine. The liquid nutraceuticals market is growing as consumers seek proactive health solutions, while gene therapies now provide cures for genetic disorders. Advanced chromatography bridges these fields. It has evolved from a laboratory tool to an essential industrial process, ensuring both high-potency vitamin drinks and viral vector injections meet safety and consistency standards. The European Dual-Track Innovation Landscape Europe leads in health innovation, particularly in preventive nutrition and advanced therapeutics. The nutraceutical market is growing steadily, supported by increased consumer awareness and clear regulations. Advanced therapeutics have also advanced quickly under the European Medicines Agency (EMA), which has approved over 15 gene therapies and is overseeing the development of several hundred more candidates. This parallel growth has created a shared need for high-resolution, scalable separation and purification technologies. Manufacturers in both sectors must achieve precise results without sacrificing efficiency or compliance, whether isolating antioxidants or purifying viral vectors. Logistics support from  Arca BioLogistics  ensures that sensitive materials are delivered reliably, complementing chromatography’s role in maintaining product consistency. Chromatography has therefore become essential for ensuring both bioavailability and safety across diverse product categories. In nutraceuticals, chromatographic techniques are primarily deployed to enhance bioavailability. In nutraceuticals, chromatography is used to improve bioavailability, potency, and consumer confidence. In gene therapies, it is vital for product safety and molecular integrity. Regulatory agencies reinforce these roles: the European Food Safety Authority (EFSA) focuses on health claims and food product purity. At the same time, the EMA enforces strict standards for Advanced Therapy Medicinal Products (ATMPs). How Are Purity Technologies Shaping Nutraceuticals and Gene Therapies? The European nutraceutical sector is shifting from traditional solid supplements to liquid formats, including tinctures, liposomal sprays, and functional beverages. Advanced chromatographic techniques, especially HILIC and LC-MS, are now standard for authenticating raw materials, standardising bioactive compound concentrations, and detecting trace contaminants that may affect clean-label claims or consumer safety. Personify Health  provides a digital health platform improving efficiency and safety monitoring, reflecting growing demand for scalable and high-resolution solutions. In contrast, gene therapies represent the frontier of pharmaceutical purification, where chromatography functions as a critical gatekeeper. Viral vectors, commonly used to deliver genetic material, must be rigorously purified to remove impurities such as host cell proteins and empty capsids—viral shells lacking therapeutic payloads that can provoke adverse immune responses. European innovators have increasingly adopted monolith chromatography columns to address these challenges. Unlike traditional bead-based systems, monoliths enable higher flow rates and improved access for large biomolecules, resulting in more efficient separation and significantly improved yields. This efficiency is particularly impactful given the exceptionally high cost of gene therapies, which can range from €1 million to €2 million per dose. A key trend in both sectors is the increasing convergence of technologies. Innovations from gene therapy manufacturing, including continuous chromatography, single-use systems, and real-time process monitoring, are now being adopted in nutraceutical production to improve efficiency and scalability. Automation is driving this change, as AI-driven, closed-loop systems provide real-time purity assessment and reduce the need for manual intervention. Sustainability is also a shared priority for these industries. European regulations are placing greater emphasis on green chromatography, promoting non-toxic solvents, supercritical fluid chromatography, and resource-efficient processes. These advancements point to a future in which precision, sustainability, and automation will shape the next generation of health and life-science manufacturing in Europe. The integration of advanced chromatography throughout healthcare marks a move toward precision health. By holding liquid supplements to the same analytical standards as gene therapies, Europe is establishing a global benchmark for safety and efficacy. As these technologies become more accessible and automated, innovation will become more affordable, expanding access to both daily wellness and transformative treatments. ...Read more

APAC's Journey in Clinical Testing Advancements

Clinical testing services form the foundation of modern healthcare, delivering critical data that supports disease diagnosis, treatment monitoring, and preventive health initiatives. Encompassing a broad spectrum of analyses on biological specimens, these services are indispensable to physicians, researchers, and patients. Within the global healthcare arena, the Asia-Pacific (APAC) region has emerged as an evolving market for clinical testing services. Marked by robust economic growth, demographic shifts, and heightened investment in healthcare infrastructure, APAC presents a compelling narrative of expansion and technological advancement in the clinical diagnostics sector. Multiple interconnected factors drive the growth of APAC's clinical testing services market. Chief among them is the steady rise in healthcare expenditure across many nations, reflecting governmental commitment and growing disposable incomes. Increased spending has expanded access to diagnostic services for larger population segments. Demographic trends also play a crucial role. The aging population in several key economies and overall population growth in others contribute to sustained demand. Older populations experience higher prevalence rates of chronic conditions such as cardiovascular diseases, diabetes, and cancer, all of which require ongoing diagnostic monitoring. Simultaneously, the region faces a substantial burden of infectious diseases, necessitating continuous surveillance and diagnostic capacity. Rising health awareness among the public further fuels demand for diagnostic services. Individuals are increasingly proactive in managing their health, resulting in greater utilization of preventive screenings and early diagnostic tests. Public health initiatives aimed at early disease detection reinforce this cultural shift toward preventive healthcare. The expanding pharmaceutical and biotechnology sectors across APAC contribute significantly to market growth. Clinical trials in the region, supported by large, diverse patient populations and improving research infrastructure, require extensive diagnostic testing, including safety, efficacy, and biomarker analyses. Market Composition and Key Segments The APAC clinical testing market is diverse, encompassing a range of test types and service providers. Testing services span from high-volume routine analyses, such as clinical chemistry panels and hematology, to specialized areas including immunology, medical microbiology, and cytology. A particularly fast-growing segment is esoteric testing—most notably molecular diagnostics and genetic testing, which supports oncology, infectious disease management, pharmacogenomics, and the diagnosis of inherited disorders, reflecting the broader shift toward personalized medicine. Service provision is typically divided between hospital-based laboratories catering primarily to inpatient and outpatient needs and independent or reference laboratories, which handle high testing volumes and specialized assays. Clinic-based laboratories also contribute, particularly in providing point-of-care testing. Public and private sector participation varies across countries, influencing service delivery models. Trends indicate increasing consolidation among service providers and strategic collaborations to expand service portfolios and geographic coverage. Technological Advancements Driving Transformation Technology serves as a critical catalyst for the sector’s ongoing transformation. Molecular diagnostics, including Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), and microarray technologies, have significantly enhanced the detection and characterization of diseases at the molecular level. NGS, in particular, facilitates comprehensive genomic profiling, supporting precision oncology and rare disease diagnosis. Laboratory automation is another key driver, improving efficiency, throughput, and accuracy while reducing turnaround times. High-volume laboratories increasingly adopt automated platforms for sample processing, analysis, and data management, utilizing robotics and integrated systems to optimize workflows. Point-of-care testing (POCT) is reshaping diagnostic service models by decentralizing testing and delivering rapid results in clinical, community, and home settings. Applications include glucose monitoring, infectious disease screening, coagulation testing, and cardiac biomarker analysis. Digitalization is profoundly influencing the sector. Digital pathology enables the creation of digital slides for analysis, storage, and remote consultation. Artificial Intelligence (AI) and Machine Learning (ML) are increasingly deployed to assist in image analysis, disease prediction, and workflow optimization. Robust Laboratory Information Management Systems (LIMS) are vital for managing the growing volume of diagnostic data, ensuring quality control, and integrating with electronic health records. Understanding the Diverse Clinical Testing Market in APAC The APAC clinical testing market is highly diverse, with developed economies characterized by mature healthcare infrastructures, advanced technologies like Next-Generation Sequencing (NGS) and digital pathology, and strong regulatory frameworks. These markets focus on specialized and esoteric testing. In contrast, emerging economies, particularly in Southeast Asia, China, and India, are rapidly expanding, with significant investments in healthcare infrastructure and a shift toward more sophisticated technologies. Although regulatory and reimbursement mechanisms vary considerably, these regions also offer cost advantages, making them attractive for outsourcing clinical trial support services. Successfully navigating the diverse regulatory landscape is crucial for market success. Laboratory operations, test approvals (especially for in vitro diagnostics), and data privacy requirements differ significantly across APAC jurisdictions. However, there is a trend toward regulatory harmonization, with many countries aligning with international standards like those set by the International Council for Harmonisation (ICH). Quality assurance and data security remain key priorities, with ISO 15189 accreditation increasingly seen as a benchmark of laboratory competence. As healthcare becomes more digital, data privacy concerns rise, further highlighting the importance of regulatory compliance. Health Technology Assessment (HTA) bodies are also emerging across the region, evaluating the clinical and economic value of diagnostic technologies to guide reimbursement and policy decisions. The clinical testing services industry is vital to the region’s healthcare landscape. Powered by robust growth drivers, shaped by technological innovation, and responsive to diverse regional needs, the sector is poised for sustained expansion. From routine health screenings to advanced genomic analyses, clinical testing services are central to enhancing patient outcomes and advancing public health. As APAC continues to experience economic and social development, the clinical diagnostics sector will be increasingly critical in enabling more accessible, efficient, and personalized healthcare across the region. ...Read more
Life Sciences Review Europe
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review Europe. All rights reserved.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesrevieweurope.com/news/the-impact-of-advanced-delivery-systems-on-the-european-nutraceutical-market-nwid-3022.html